Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1969 1
1972 2
1999 1
2000 2
2001 5
2002 1
2005 1
2006 5
2007 1
2008 1
2010 3
2011 2
2012 1
2014 3
2015 3
2016 5
2017 3
2018 1
2019 5
2020 2
2021 2
2022 4
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Del Campo JM, et al. Among authors: hazard sj. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7. J Clin Oncol. 2019. PMID: 31173551 Free PMC article. Clinical Trial.
Awake craniotomies in the pediatric population: a systematic review.
Bhanja D, Sciscent BY, Daggubati LC, Ryan CA, Pahapill NK, Hazard SW, Rizk EB. Bhanja D, et al. Among authors: hazard sw. J Neurosurg Pediatr. 2023 Jun 30;32(4):428-436. doi: 10.3171/2023.4.PEDS22296. Print 2023 Oct 1. J Neurosurg Pediatr. 2023. PMID: 37410631
Safety and dose modification for patients receiving niraparib.
Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Berek JS, et al. Among authors: hazard s. Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181. Ann Oncol. 2018. PMID: 29767688 Free article. Clinical Trial.
Defining the CD59-C9 binding interaction.
Huang Y, Qiao F, Abagyan R, Hazard S, Tomlinson S. Huang Y, et al. Among authors: hazard s. J Biol Chem. 2006 Sep 15;281(37):27398-404. doi: 10.1074/jbc.M603690200. Epub 2006 Jul 14. J Biol Chem. 2006. PMID: 16844690 Free article.
Safety and dose modification for patients receiving niraparib.
Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Berek JS, et al. Among authors: hazard s. Ann Oncol. 2019 May 1;30(5):859. doi: 10.1093/annonc/mdy255. Ann Oncol. 2019. PMID: 30107447 Free article. No abstract available.
54 results